Policy & Regulation
FDA grants Breakthrough Therapy designation to Clarity Pharmaceuticals' prostate cancer imaging agent
12 November 2026 - Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals Ltd (ASX: CU6) said on Thursday the US Food and Drug Administration (FDA) has granted Breakthrough Ther...
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
12 November 2026 - Clinical-stage biopharmaceutical company Traws Pharma, Inc. (NASDAQ: TRAW) on Thursday reported final results from a 92-patient Phase 2a study of ratutrelvir, its investigational on...
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
12 November 2026 - Shanton Pharma, a China-based, clinical-stage biotech developing a novel treatment for hyperuricaemia and gout in adults, announced on Wednesday that it has reached an agreement wit...
Lilly's Taltz and Zepbound combination delivers sustained psoriatic arthritis improvements at one year
11 November 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) on Wednesday reported 52-week Phase 3b results showing sustained improvements in disease activity, physical function and metabolic...
Ascletis announces submission of US IND application for oral obesity combination therapy
11 November 2026 - Biotechnology company Ascletis Pharma Inc (HKEX: 1672) reported on Wednesday that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administrati...
Jubilant Therapeutics to present LSD1 and HDAC6 (CoREST) orally administered dual inhibitor Phase 1/2 study results at 68th ASH Annual Meeting
11 November 2026 - Jubilant Therapeutics Inc, a US-based, clinical-stage biopharmaceutical company that is advancing precision therapeutics for myeloproliferative neoplasms (MPNs), announced on Tuesda...